APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitor Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PD-1 and PD-L1 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1 and PD-L1 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1 and PD-L1 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1 and PD-L1 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1 and PD-L1 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1 and PD-L1 Inhibitor Segment by Company

Bristol Myers Squibb

Bristol-Myers Squibb

Regeneron Pharmaceuticals

AstraZeneca

Beigene

Hengrui Medicine

Pfizer

Junshi Biosciences

Akeso

Alphamab Oncology

Roche

Merck

Sanofi

Innovent Biologics

PD-1 and PD-L1 Inhibitor Segment by Type

Monoclonal Antibody

Bispecific Antibody

PD-1 and PD-L1 Inhibitor Segment by Application

Lung Cancer

Breast Cancer

Stomach Cancer

Rectal Cancer

Others

PD-1 and PD-L1 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PD-1 and PD-L1 Inhibitor Industry Trends Table 2. PD-1 and PD-L1 Inhibitor Industry Drivers Table 3. PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges Table 4. PD-1 and PD-L1 Inhibitor Industry Restraints Table 5. Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers Table 9. Global PD-1 and PD-L1 Inhibitor Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global PD-1 and PD-L1 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PD-1 and PD-L1 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PD-1 and PD-L1 Inhibitor Manufacturers, Product Type & Application Table 13. Global PD-1 and PD-L1 Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1 and PD-L1 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monoclonal Antibody Table 17. Major Manufacturers of Bispecific Antibody Table 18. Global PD-1 and PD-L1 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 19. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 20. Global PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 21. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2026) Table 22. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2027-2032) Table 23. Global PD-1 and PD-L1 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 24. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (Tons) Table 25. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (Tons) Table 26. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2026) Table 27. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Lung Cancer Table 29. Major Manufacturers of Breast Cancer Table 30. Major Manufacturers of Stomach Cancer Table 31. Major Manufacturers of Rectal Cancer Table 32. Major Manufacturers of Others Table 33. Global PD-1 and PD-L1 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 35. Global PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 36. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2026) Table 37. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2027-2032) Table 38. Global PD-1 and PD-L1 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 39. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (Tons) Table 40. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (Tons) Table 41. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2026) Table 42. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2027-2032) Table 43. Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (Tons) Table 45. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global PD-1 and PD-L1 Inhibitor Sales Forecasted by Region (2027-2032) & (Tons) Table 47. Global PD-1 and PD-L1 Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 48. North America PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 49. North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 50. North America PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 51. Europe PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 52. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 53. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 54. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 56. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 57. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 58. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 59. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 60. Global PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 62. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 63. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2026) Table 64. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2027-2032) Table 65. Bristol Myers Squibb Company Information Table 66. Bristol Myers Squibb Business Overview Table 67. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 69. Bristol Myers Squibb Recent Development Table 70. Bristol-Myers Squibb Company Information Table 71. Bristol-Myers Squibb Business Overview Table 72. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 74. Bristol-Myers Squibb Recent Development Table 75. Regeneron Pharmaceuticals Company Information Table 76. Regeneron Pharmaceuticals Business Overview Table 77. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio Table 79. Regeneron Pharmaceuticals Recent Development Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio Table 84. AstraZeneca Recent Development Table 85. Beigene Company Information Table 86. Beigene Business Overview Table 87. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Beigene PD-1 and PD-L1 Inhibitor Product Portfolio Table 89. Beigene Recent Development Table 90. Hengrui Medicine Company Information Table 91. Hengrui Medicine Business Overview Table 92. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio Table 94. Hengrui Medicine Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio Table 99. Pfizer Recent Development Table 100. Junshi Biosciences Company Information Table 101. Junshi Biosciences Business Overview Table 102. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio Table 104. Junshi Biosciences Recent Development Table 105. Akeso Company Information Table 106. Akeso Business Overview Table 107. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Akeso PD-1 and PD-L1 Inhibitor Product Portfolio Table 109. Akeso Recent Development Table 110. Alphamab Oncology Company Information Table 111. Alphamab Oncology Business Overview Table 112. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio Table 114. Alphamab Oncology Recent Development Table 115. Roche Company Information Table 116. Roche Business Overview Table 117. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Roche PD-1 and PD-L1 Inhibitor Product Portfolio Table 119. Roche Recent Development Table 120. Merck Company Information Table 121. Merck Business Overview Table 122. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Merck PD-1 and PD-L1 Inhibitor Product Portfolio Table 124. Merck Recent Development Table 125. Sanofi Company Information Table 126. Sanofi Business Overview Table 127. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio Table 129. Sanofi Recent Development Table 130. Innovent Biologics Company Information Table 131. Innovent Biologics Business Overview Table 132. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio Table 134. Innovent Biologics Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. PD-1 and PD-L1 Inhibitor Distributors List Table 138. PD-1 and PD-L1 Inhibitor Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitor Product Image Figure 2. Global PD-1 and PD-L1 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1 and PD-L1 Inhibitor Sales (2021-2032) & (Tons) Figure 5. Global PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monoclonal Antibody Image Figure 9. Bispecific Antibody Image Figure 10. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 11. Global PD-1 and PD-L1 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032) Figure 13. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global PD-1 and PD-L1 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032) Figure 16. Lung Cancer Image Figure 17. Breast Cancer Image Figure 18. Stomach Cancer Image Figure 19. Rectal Cancer Image Figure 20. Others Image Figure 21. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global PD-1 and PD-L1 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032) Figure 24. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 25. Global PD-1 and PD-L1 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032) Figure 27. North America PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 28. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 29. U.S. PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 30. Canada PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 31. Mexico PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 32. Europe PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 33. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 34. Germany PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 35. France PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 36. U.K. PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 37. Italy PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 38. Netherlands PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 39. Asia Pacific PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 40. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 41. China PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Japan PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 43. South Korea PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Southeast Asia PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 45. India PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 46. Australia PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 47. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 48. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 49. Brazil PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 50. South Africa PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 51. Saudi Arabia PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 52. Turkey PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 53. Argentina PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 54. UAE PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Egypt PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 56. Chile PD-1 and PD-L1 Inhibitor Sales and Growth Rate (2021-2032) & (Tons) Figure 57. Global PD-1 and PD-L1 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 60. North America PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 62. Europe PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. PD-1 and PD-L1 Inhibitor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. PD-1 and PD-L1 Inhibitor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Bispecific Antibody
Applications
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Others
Companies covered
  • Bristol Myers Squibb
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Beigene
  • Hengrui Medicine
  • Pfizer
  • Junshi Biosciences
  • Akeso
  • Alphamab Oncology
  • Roche
  • Merck
  • Sanofi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-1 and PD-L1 Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PD-1 and PD-L1 Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PD-1 and PD-L1 Inhibitor Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitor Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitor Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitor Industry Restraints
3 PD-1 and PD-L1 Inhibitor Market by Manufacturers
  1. 3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1 and PD-L1 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PD-1 and PD-L1 Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global PD-1 and PD-L1 Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1 and PD-L1 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1 and PD-L1 Inhibitor Tier 1, Tier 2, and Tier 3
4 PD-1 and PD-L1 Inhibitor Market by Type
  1. 4.1 PD-1 and PD-L1 Inhibitor Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 Bispecific Antibody
  4. 4.2 Global PD-1 and PD-L1 Inhibitor Sales by Type
  5. 4.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  7. 4.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032)
  8. 4.3 Global PD-1 and PD-L1 Inhibitor Revenue by Type
  9. 4.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  11. 4.3.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032)
5 PD-1 and PD-L1 Inhibitor Market by Application
  1. 5.1 PD-1 and PD-L1 Inhibitor Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Stomach Cancer
  5. 5.1.4 Rectal Cancer
  6. 5.1.5 Others
  7. 5.2 Global PD-1 and PD-L1 Inhibitor Sales by Application
  8. 5.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  10. 5.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032)
  11. 5.3 Global PD-1 and PD-L1 Inhibitor Revenue by Application
  12. 5.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  14. 5.3.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032)
6 Global PD-1 and PD-L1 Inhibitor Sales by Region
  1. 6.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global PD-1 and PD-L1 Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PD-1 and PD-L1 Inhibitor Revenue by Region
  1. 7.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region
  2. 7.1.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PD-1 and PD-L1 Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PD-1 and PD-L1 Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Regeneron Pharmaceuticals
  14. 8.3.1 Regeneron Pharmaceuticals Company Information
  15. 8.3.2 Regeneron Pharmaceuticals Business Overview
  16. 8.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
  18. 8.3.5 Regeneron Pharmaceuticals Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Beigene
  26. 8.5.1 Beigene Company Information
  27. 8.5.2 Beigene Business Overview
  28. 8.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
  30. 8.5.5 Beigene Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Junshi Biosciences
  44. 8.8.1 Junshi Biosciences Company Information
  45. 8.8.2 Junshi Biosciences Business Overview
  46. 8.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
  48. 8.8.5 Junshi Biosciences Recent Developments
  49. 8.9 Akeso
  50. 8.9.1 Akeso Company Information
  51. 8.9.2 Akeso Business Overview
  52. 8.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
  54. 8.9.5 Akeso Recent Developments
  55. 8.10 Alphamab Oncology
  56. 8.10.1 Alphamab Oncology Company Information
  57. 8.10.2 Alphamab Oncology Business Overview
  58. 8.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
  60. 8.10.5 Alphamab Oncology Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Innovent Biologics
  80. 8.14.1 Innovent Biologics Company Information
  81. 8.14.2 Innovent Biologics Business Overview
  82. 8.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
  84. 8.14.5 Innovent Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
  2. 9.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1 and PD-L1 Inhibitor Production Mode & Process
  6. 9.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1 and PD-L1 Inhibitor Distributors
  9. 9.2.3 PD-1 and PD-L1 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst